year rHuEPO therapy prolongs RBC survival RBC membranes natural progression chronic renal failure uremia need dialysis rHuEPO patients chronic renal failure CRF uremia year Creatinine Clearance GFR ml/min Hct Baseline RBC survival GFR average days Repeat months GFR ml/min Hct days year days Hct GFR ml/min need dialysis Reticulocytes weeks months year Bone marrow cellularity months year ratio months year Marrow iron months year Doses rHuEPO polycythemia stimulates pts progressive CRF year initial increase hematocrit due early peak reticulocytes months rHuEPO hematocrit mechanisms reticulocytosis trend bone marrow erythroid cellularity RBC survival year rHuEPO therapy trend marrow cellularity maintenance target hematocrit lengthened RBC survival progression CRF rHuEPO RBCs survival RBC membranes rHuEPO 